Table 1.

Selections of currently available molecular diagnostic platforms are shown in relation to the genomic alterations these tests are poised to target

Selected therapeutically relevant genomic alterations in NSCLC	Sanger sequencing	Immunohistochemistry	Fluorescence in situ hybridization	Multiplex hotspot mutation testing	Multiplex sizing assays	Anchored multiplex PCR RNA sequencing	Next-generation DNA sequencing
Point mutations
EGFR	✓	✓		✓		✓	✓
KRAS		(EGFR L858R)
ERBB2 (HER2)
MAP2K1 (MEK)
BRAF
PIK3CA
AKT
Insertions or deletions
EGFR	✓	✓			✓	✓	✓
ERBB2 (HER2)		(EGFR exon 19 deletion)
Rearrangements
ALK		✓	✓			✓	✓
ROS1		(ALK and ROS1 require FISFI confirmation)				(Novel fusion detection)
RET
NTRK
Amplification/loss
MET		✓	✓			✓	✓
PTEN		(MET amplification requires FISFI confirmation)
Non-recurrent genomic alterations
Other potentially relevant oncogenes and tumor suppressor genes							✓

For multiplex platforms and next-generation sequencing, the genomic alterations that are interrogated by these assays often can be customized based on histology and clinical need